Drug Discovery Biology
Glue Logic: How Molecular Glue Degraders are Redrawing The Map of Druggability
Molecular glue degraders represent a mechanistic shift from blocking protein function to engineering the cellular conditions under which problematic proteins are selectively destroyed.
Open Nucleotides: Grant-Driven Infrastructure for Equitable mRNA Vaccine Manufacturing
By developing accessible cap analogs and RNA raw materials, Hongene Biotech, guided by David Butler’s expertise in nucleotide chemistry and supported by the Gates Foundation, is reshaping the molecular infrastructure that underpins global mRNA vaccine equity.
Aptamer Signal Dynamics: Engineering Nucleic Acid Recognition Systems for High-Fidelity, Multi-Modal Biosensing
Aptamers redefine biosensing by pairing programmable molecular recognition with versatile transduction strategies capable of detecting clinically relevant biomarkers with exceptional fidelity.
Venom Meets Hub-Proteins: Computational Forecasting of Calloselasma rhodostoma-Derived Peptides Targeting Cancer Network Hubs
Computational screening of C. rhodostoma venom peptides against cancer hub proteins suggests a promising peptide-drug discovery avenue bridging toxin biology and network oncology.
Molecular Space Evo-Signatures: Integrating Chemical Substructures and Protein Evolution to Decode Drug–Target Interactions
Fusing protein evolution with chemical substructures reveals a unified, data-driven path to predicting how drugs recognize and bind their molecular targets.
Lactate–Pyruvate Redox Control: How LDH Orchestrates Electron Economy, ROS Signaling, and Resilience
By tuning the lactate–pyruvate valve to maintain the NADH/NAD⁺ ratio, lactate dehydrogenase orchestrates ROS containment, metabolic flexibility, and tissue-level robustness.
